OncoImmune Ltd

15 articles with OncoImmune Ltd

• 

  Biopharma Update on the Novel Coronavirus: November 24

  11/24/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.
• 

  Merck Bolsters COVID-19 Pipeline with OncoImmune Acquisition

  11/23/2020

  Merck acquired OncoImmune and its COVID-19 therapeutic candidate CD24Fc for $425 million in upfront cash two months after the Phase III asset demonstrated efficacy during an interim analysis.

• OncoImmune’s SACCOVID™ (CD24Fc) Exhibits Superb Therapeutic Efficacy—A Potential Breakthrough in Treating Severe and Critical COVID-19

  9/24/2020

  OncoImmune’s SACCOVID ™ (CD24Fc) Exhibits Superb Therapeutic Efficacy—A Potential Breakthrough in Treating Severe and Critical COVID-19

• OncoImmune Launches First-in-human Clinical Trial for ONC-392 – The anti-CTLA-4 Antibody that Preserves CTLA4 Recycling for Safer and More Effective Immunotherapy

  9/23/2020

  OncoImmune, Inc. announced today that it has dosed the first patient in the first-in-human clinical trial of ONC-392, its novel, next generation anti-CTLA-4 antibody, at the University of California (UC) Davis Comprehensive Cancer Center on September 16, 2020. This is a Phase 1A/1B clinical trial designed to assess the safety, pharmacokinetics, and clinical activity of ONC-392 as a single agent in advanced solid tumors a

• OncoImmune, Inc. Raises $56 Million Series B Financing for Novel Cancer and COVID-19 Therapeutics

  9/9/2020

  OncoImmune, Inc. announced the completion of a $56 million financing in Series B equity co-led by HM Capital and a blue-chip investor.

• 

  OncoImmune Raises $56 Million to Advance Anti-Inflammatory and Oncology Pipeline

  9/9/2020

  Rockville, Maryland-based OncoImmune closed on a Series B round worth $56 million.

• OncoImmune, Inc. Reports Progress on its Phase III Clinical Trial testing CD24Fc for Severe and Critical COVID-19

  6/14/2020

  OncoImmune, Inc. reached an important milestone in its Phase III clinical trial testing the safety and clinical efficacy of CD24Fc for severe and critical COVID-19 patients on June 9, 2020.

• OncoImmune Starts Phase III Clinical Trial Testing the Power of Dampening Inflammation to Virus-induced Cellular Injury in Severe COVID-19 Patients

  4/21/2020

  OncoImmune, Inc. initiated its Phase III clinical trial testing the safety and efficacy of CD24Fc in hospitalized COVID-19 patients at the University of Maryland Baltimore Medical Center on April 20, 2020.

• OncoImmune Receives FDA Approval for COVID-19 Clinical Trial

  4/8/2020

  OncoImmune, Inc. has received a study-may-proceed letter from the FDA for its Phase III clinical trial testing the safety and efficacy of CD24Fc for the treatment of hospitalized COVID-19 patients (SAC-COVID).

• OncoImmune Announces Presentation of CD24Fc Phase IIa Data and Phase III Clinical Trial Design at the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

  1/27/2020

  OncoImmune, Inc. announced that clinical data from its Phase IIa clinical trial of CD24Fc are being presented at the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Meeting, taking place in Orlando, Florida in February.

• CoImmune Inc., a US-based clinical-stage biotech, and Formula Pharmaceutical Inc. agree to merge in an all-stock transaction

  1/15/2020

  CoImmune, Inc. and Formula Pharmaceuticals, Inc. announced the merger between the two companies, bringing together two therapeutic immuno-oncology platforms.

• OncoImmune Announces Approval of IND Application for ONC-392 – The anti-CTLA-4 Antibody that Preserves CTLA-4 Recycling for Better Safety and Efficacy

  12/30/2019

  OncoImmune, Inc. announced today that its Investigational New Drug application for ONC-392, its novel, next generation anti-CTLA-4 antibody, has been approved by the U.S. Food and Drug Administration.

• OncoImmune Announces Completion of Phase II Trial

  1/10/2019

  The Phase IIa trial is a multicenter prospective randomized study designed to determine the MTD of CD24Fc for acute GVHD prophylaxis.

• OncoImmune Release: Biopharma Announces Series A Financing

  1/12/2017

• Tiny OncoImmune Nabs $250 Million+ Deal With Drug Giant Pfizer

  9/15/2016